Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus chemotherapy in lung cancer with inactive pulmonary tuberculosis
ChiCTR2000041449Phase 2Recruiting
- Sponsor
- Infectious Disease Hospital of Heilongjiang Province
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in bronchial carcinoma and pulmonary tuberculosis (TB), sponsored by Infectious Disease Hospital of Heilongjiang Province. Primary endpoint: objective response rate. Started Dec 2020; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
bronchial carcinomapulmonary tuberculosis (TB)
Beyond the preview
Go deeper on ChiCTR2000041449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041449.